Clinical trials: Myeloma Multiple
Multiple Myeloma
Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L
The purpose of this study is to compare the effects, good and bad, of two ways to treat patients with standard-risk symptomatic multiple myeloma.
- Trial name
- NCT00807599
- Testing
- Stem cell transplant x 1 or x 2, lenalidomide and dexamethasone
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Non-Hodgkin's Lymphoma
An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)
The primary purpose of this Phase I study is to evaluate the effect of the co-administration of CYP3A4 inducers on the pharmacokinetics profile of VELCADE (bortezomib).
- Trial name
- NCT00608907
- Testing
- bortezomib, bortezomib, rifampicin, bortezomib, dexamethasone
- Where
- 9 sites in Israel, Italy and 3 more
- Volunteers
- 61 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
This Phase II clinical trial was designed for patients with hematologic malignancies in need of donor peripheral blood stem cell transplant, and have no HLA matched donor.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT01116232
- Testing
- anti-thymocyte globulin, rituximab, sirolimus
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
RATIONALE: Low dose deferasirox may be safe and effective in treating patients who have undergone hematopoietic stem cell transplant and have iron overload.
- Conditions
- Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT01159067
- Testing
- deferasirox
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma
MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma
This study evaluates a new drug MGTA-145 in combination with plerixafor (Mozobil) to mobilize stem cells into the peripheral blood for collection by apheresis.
- Trial name
- NCT04552743
- Testing
- MGTA-145, Plerixafor
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Surbhi Sidana, MD
Multiple Myeloma, Advanced Solid Tumors
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment
The purpose of this study is to characterize the single-dose pharmacokinetic (PK) parameters of ixazomib (MLN9708) in cancer participants with either normal renal function or severe renal impairment (RI), including participants…
- Trial name
- NCT01830816
- Testing
- Ixazomib
- Where
- 11 sites in United States, Canada
- Volunteers
- 41 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
AL Amyloidosis
The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis
This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who…
- Trial name
- PRONTO (NCT02632786)
- Testing
- NEOD001
- Where
- 40 sites in United States, Australia and 8 more
- Volunteers
- 129 people
- Sponsor
- Prothena Biosciences Ltd.
Multiple Myeloma
Redirected Auto T Cells for Advanced Myeloma
The purpose of this study is to 1) evaluate the safety and tolerability of autologous genetically modified T cells transduced to express the high affinity NY-ESO-1c259 TCR in HLA-A2+ subjects and 2) measure the incidence of GVHD…
- Trial name
- NCT01352286
- Testing
- Autologous Genetically modified T cells
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Myeloma, Endometrial Cancer
Positron Emission Tomography (PET) Imaging Studies With NIS Reporter
The goal of this proposal is to perform first-in-man evaluation of and experimental imaging agent F-18 tetrafluoroborate (BF4) or (TFB).
- Trial name
- NCT02907073
- Testing
- BF4
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer, Colorectal Cancer
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
This research study will test the efficacy of interactive, web-based interventions that improve diet, physical activity and weight management changes among early stage survivors of breast, prostate, colorectal, endometrial…
- Conditions
- Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer
- Trial name
- AMPLIFY (NCT04000880)
- Testing
- Adapting MultiPLe Behavior Interventions That eFfectively Improve (AMPLIFI) Cancer Survivor Health, Diet-Exercise, Exercise-Diet
- Where
- 2 sites in United States
- Volunteers
- 603 people
- Sponsor
- University of Alabama at Birmingham
Multiple Myeloma
Uproleselan (GMI-1271) for GI Toxicity Prophylaxis During Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Multiple Myeloma (MM)
The investigators hypothesize that prophylactic E-selectin inhibition via administration of uproleselan during melphalan conditioning will reduce the gastrointestinal (GI) toxicity in multiple myeloma (MM) patients undergoing…
- Trial name
- NCT04682405
- Testing
- Uproleselan, Melphalan
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Washington University School of Medicine
Myeloma
Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
One purpose of this study is to find out if a new combination of immune system treatments (MAGE-A3 vaccine plus activated T-cells) will allow the body to build up protection ("immunity") against the myeloma cells.
- Trial name
- NCT01245673
- Testing
- Prevnar- Pneumococcal Conjugate Vaccine (PCV), Activated/costimulated autologous T-cell, Revlamid® (Lenalidomide)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of Pennsylvania
Multiple Myeloma, Non-Hodgkin's Lymphoma
Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
The treatments used to treat lymphoma and multiple myeloma sometimes do not always work well or they may only work for a short period of time. This is why new treatments are being tested.
- Trial name
- NCT01755975
- Testing
- Romidepsin, Lenalidomide
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma
UARK 89-001 Phase II Study of Intensive "TOTAL THERAPY" For Untreated or Minimally Treated Patients With Multiple Myeloma
This experimental study evaluates the effects of a series of intensive drug regimens as initial treatment for Multiple Myeloma followed by 2 bone marrow transplantations 4-6 months apart in support of high-dose Melphalan…
- Trial name
- NCT00580372
- Testing
- VAD, High-Dose cyclophosphamide, Hemopoietic stem cell procurement
- Where
- United States
- Volunteers
- 231 people
- Sponsor
- University of Arkansas
Multiple Myeloma
Preemptive Strike With Bortezomib in Multiple Myeloma Patients
To evaluate whether using the drug bortezomib at the start of remission will prevent relapse for a longer period of time.
- Trial name
- 2007-77 (NCT00657553)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Arkansas
Multiple Myeloma
Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma
The hypothesis for this study is that the regimen consisting of fludarabine, melphalan and bortezomib improves the progression free survival and the response rate compared to historical controls of fludarabine and melphalan alone.
- Trial name
- Flu-Mel-Vel (NCT01453101)
- Testing
- Fludarabine monophosphate, melphalan, Bortezomib
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Hackensack Meridian Health
Chemotherapy-induced Peripheral Neuropathy
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
This randomized, controlled trial is designed to evaluate the effect of acupuncture on Chemotherapy-Induced Peripheral Neuropathy (CIPN), other symptoms, and potential opioid and concomitant medication sparing effects in…
- Trial name
- NCT04770402
- Testing
- Acupuncture, Standard of Care CIPN management
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Wake Forest University Health Sciences
Multiple Myeloma
Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide
The purpose of this study is determine Time-to-Progression with elotuzumab plus lenalidomide when elotuzumab is added to multiple myeloma participants with serologic relapse/progression while receiving lenalidomide maintenance…
- Trial name
- NCT03411031
- Testing
- Elotuzumab, Lenalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Multiple Myeloma
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.
- Trial name
- NCT05090566
- Testing
- Elranatamab + Nirogacestat, Elranatamab + lenalidomide + dexamethasone
- Where
- 25 sites in United States, Canada
- Volunteers
- 46 people
- Sponsor
- Pfizer
Refractory Multiple Myeloma, Stage I Multiple Myeloma
Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy, such as pegylated liposomal doxorubicin hydrochloride and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from…
- Conditions
- Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Trial name
- NCT00849251
- Testing
- cyclophosphamide, pegylated liposomal doxorubicin hydrochloride, bortezomib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Washington